Preclinical studies have demonstrated that surufatinib decreased M2 tumor-associated macrophages (TAMs) and increased M1 TAMs, and this immune-modulation effect might result in enhanced anti-tumor effect when surufatinib is combined with anti-PD-1/PD-L1 antibody (Zhou et al. 2017). This evidence concerns the gene CD274 and neoplasm.